Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30992286 | 0.94 | MAPT (0.44) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL30541889 | 0.83 | MAPT (0.40) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL25807645 | 0.81 | PTPN1 (0.34) | MAPTALDH1A1NR1H2NR1H3PTPN1 | |
| SCHEMBL12686993 | 0.81 | PTPN1 (0.35) | MAPTNFKB1NFKB2RELANR1H2 | |
| SCHEMBL6480393 | 0.81 | PTPN1 (0.35) | MAPTNFKB1NFKB2RELANR1H2 | |
| SCHEMBL15896630 | 0.81 | MAPT (0.38) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL18593159 | 0.81 | MAPT (0.38) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL12423750 | 0.81 | MAPT (0.38) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL8214876 | 0.81 | MAPT (0.38) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL18593158 | 0.81 | MAPT (0.38) | MAPTMEN1KMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612156-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20240199647-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-20 | — | — | US | disclosed |
| US-11993600-B2 | Saturated spirocyclics as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2024097296-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20230174531-A1 | SATURATED SPIROCYCLICS AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11993600-B2 | Saturated spirocyclics as antiviral agents | ACE, ACE2, PKD1 | MAPT 4475/4885MEN1 3626/4885KMT2A 4141/4885 |
| US-20230174531-A1 | SATURATED SPIROCYCLICS AS ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | MAPT 4475/4885MEN1 3626/4885KMT2A 4141/4885 |
| US-20240199647-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | MAPT 1485/4885MEN1 1494/4885KMT2A 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.